Costs of generic drugs and outpatient services targeted
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
This content was published on
2 minutes
swissinfo.ch/urs
Interior Minister Alain Berset, whose portfolio includes health issues, on Friday presented plans to allow health insurers, health service providers and cantonal authorities to launch pilot projects to test innovative financing methods for hospital care or outpatient services.
The package will go to a consultation among political parties, organisations and institutions involved before parliament is due to discuss the final proposals. It is expected to lead to a savings of several hundred million francs per year, according to Berset.
He added that it won’t be easy to find support for all the proposed measures, given the ongoing dispute between insurers, doctors, the pharmaceutical industry and cantonal authorities, notably about a billing system for doctors.
Mixed reaction
In an initial reaction, the industry associations of Swiss pharmacistsExternal link and producers of generics have rejected the government proposal. They warned that patients would no longer be free to choose their favourite therapy.
For their part, the association of health insurers welcomed the plans , saying they were a step in the right direction.
SantésuisseExternal link notably called for cheaper drugs prices and more say in the construction of hospitals and nursing homes as well as increased cost transparency.
Financial caps
A second package of proposals is expected to be presented next year, including financial caps for medical costs, as recommended by a group of experts in 2016.
Overall health costs in Switzerland are about CHF80 billion ($82.6 billion) annually, including CHF30 billion covered by the mandatory health insurance plans.
The Swiss healthcare system is known for its excellent level of care, but is also among the most expensive in the world.
This content was published on
Nemo brought the Eurovision Song Contest to Switzerland with a victory on Saturday evening in Malmö, Sweden. It is Switzerland's third victory in the history of the music contest.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
National conference divided on how to halt rising healthcare costs
This content was published on
The fifth Swiss national health conference on Monday centred on one major bugbear: costs. Attendees were divided on how to halt the rise.
This content was published on
The Swiss spend more from their own pockets for health care than any other nation, according to a survey for the price comparison website Comparis.
This content was published on
Interior Minister Alain Berset says he is willing to consider the introduction of a global budget for Switzerland’s healthcare system as part of efforts to reduce rising health costs.
This content was published on
In an era where health care is a subject of debate in many countries, is the Swiss system serving those on moderate to low incomes?
Novartis’s new $475,000 cancer drug among most expensive ever
This content was published on
Bruno Strigini, chief executive of oncology at Novartis, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.” He was speaking on Wednesday shortly after the treatment was approved by the US Food and Drug Administration (FDA), which gave Novartis a green light to use the medicine…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.